Member Info for MadChatter

Do we have any numbers on this?

Sorry to hear about your friend airlineboy

Not to mention selling to other countries, or the public...

Hopefully this has a solid floor at 9.8 / 10p

Show me one pharma/ biotech company that is ever valued based on revenue in the early stages? If this were it would be sitting nearer 500k mcap Haha.

You are right, there's a logical balance point somewhere.

I do know if this were nasdaq listed it would probably be at least 50m mcap.

With the director share options vesting around 50p, and a direct message of exponential growth, it should be pretty clear where this is going now.

In fairness this has spent years around 5p. A lot of pi would be taking profits. But every one that sells being replaced by a holder at 15p+ etc.

Depends. They could do any of a few combinations. All share, all cash, or something in between.

All cash means special huge dividend but our shares become worthless.

All share they decide a suitable conversion. Example 1 new share per 100 iqai.

Or something inbetween.

Basically, considering this is fda approved (north America), if this were Nasdaq listed instead it would easily be worth $100m now.

I forget the exact name, but I think someone suggested Regeneron Pharmaceutical yesterday

They don't mean anything at all. Just market makers balancing the books. Can ignore

I'd say if we can close above 17 on a day when the ftse is down it's a good day!

I think we are seeing a very gradual shift from pi to ii since yesterday lunch.

I was just number crunching from the Rns

Someone correct me if I'm wrong on anything here. £2k to £3k per person. 2bn people. Theoretically £6tn market. Obviously we would sell our products substantially cheaper.

We are the market leaders and have any competition??

And people are selling for peanuts!? :D

Also, you have to remember because this is only about 50% free float it's much less likely they will rip everyone off with a stupidly low placing price. The ii would sure have strong words if they did...

I may be wrong, but if they a strong sales pipeline they would be very silly to raise just on FDA approval. Much better to wait until a decent order is made

All this time waiting for fda approval I am certain they must have some big deals lined up already

@rob

NYCt went well over £100m before seeing any real profits

I'd say 0.1 is the target here. If I understand the maths correctly

I'm confused when is the deadline for shorecan now.?

I thought it was 4th Aug, but they resolved dispute then, are we awaiting some further deadline?